What if the market is measuring these companies by what they are today instead of what they could become? 👀

We’ll look at the growth engines behind four overlooked stocks, what has to go right for each thesis to work, and the warning signs that could change the story.

Read through to the end — the framework at the close is the part most busy investors can reuse every week.

"The big money is not in the buying and selling, but in the waiting."

— Charlie Munger

A fixed $500 a month is a waiting tool: you keep adding while the chart looks boring, without needing to time the breakout.

Celestica Inc. $CLS ( ▲ 3.54% ) closed at $332.63. Five years earlier it was about $9.46. That is a +$323.17 move, or +3,416.17% in total — roughly 104%/yr on average if you held the whole stretch. That pace is extreme. It is not a forecast, and it is a poor default to project forward blindly.

Look for on the chart: the quiet stretch into 2024, the 2025–2026 climb toward the $474.02 52-week high, and the pullback to $332.63 (52-week low $227.00) — DCA would have bought many more shares in the early years and fewer into the late strength.

Lesson: Late compounding. Almost all of this five-year gain arrived in the back half of the window. Past results never guarantee the future — a 104%/yr average is a historical outlier, not a coupon you can clip again.

Next Horizon: another verified 5-year chart, same $500/month frame, same honest catch.

Want a cleaner look at this name? Open CLS on Snowball Analytics — price, fundamentals, and history in one place. Context for the chart above, not a buy signal.

Invest long-term. Get the Fast Track blueprint.

CLS is the waiting math — the blueprint turns that into a $500 habit with broker setup and a clear portfolio start.

Sponsored resource

The most interesting opportunities are not always the stocks everyone is talking about. Sometimes the better question is what the business could look like several years from now if management keeps executing while the market stays focused on shorter-term concerns.

That is the idea behind Broadcom (AVGO), Oscar Health (OSCR), Voyager Technologies (VOYG), and Nu Holdings (NU) — four very different growth engines that could become considerably larger than they are today if earnings, revenue, and cash flow compound for years.

Broadcom $AVGO ( ▲ 1.6% ) is already one of the world’s largest semiconductor and infrastructure companies, with roughly $40.65 billion in operating cash flow over the last 12 months cited, operating margin near 48%, and free-cash-flow margin around 44.2%.

The next phase is custom AI accelerators and networking. Hyperscalers including Google, OpenAI, Anthropic, and Meta want specialized chips for their own workloads — which does not require Broadcom to replace Nvidia. The AI market can leave room for GPUs and custom silicon at the same time.

Source projections are aggressive (revenue potentially near $272.7 billion by fiscal 2028). Those are forecasts, not guarantees — but if AI infrastructure spend keeps expanding, Broadcom can remain a major beneficiary at scale.

Oscar Health $OSCR ( ▼ 2.61% ) is still small versus the U.S. healthcare market, yet revenue has risen roughly sevenfold since 2021 and membership is near 3 million (vs. 1.6 million in 2024). Management targets more than 20% CAGR revenue growth from 2026–2029, 5%–7% operating margins, and more than $4 EPS by 2029.

Beyond membership, Oscar is pushing employer-funded individual coverage and Lucy, its marketplace platform (management has described a very large addressable opportunity). AI tools that resolve a meaningful share of member messages, plus medical-cost savings, matter as much as growth — insurance is a cost-control game.

Healthcare is highly regulated. The thesis works if share gains and operating leverage stick; it weakens quickly if medical costs, pricing, or membership trends move the wrong way.

Voyager Technologies $VOYG ( ▲ 4.99% ) is the most speculative name here: ~$2.2 billion market cap, still unprofitable, with very high projected revenue growth that could approach ~$1 billion by fiscal 2028 if estimates hold.

It sits in space and defense, with expansion stories around the Golden Dome buildout, the lunar economy, and Starlab. Backlog near $336 million as of Q2, plus Astrobotic and NASA lunar-lander awards, show the story is not purely theoretical.

Execution is the risk. If Starlab or major contracts stall, a large part of the growth thesis has to be rethought. Treat this as a higher-risk bet on turning contracts into a much larger commercial business — not a conventional growth stock.

Nu Holdings $NU ( ▲ 3.0% ) (~$66.7 billion market cap) already has nearly 140 million customers across Brazil, Mexico, and Colombia. Q2 net income was about $1.1 billion (~49% YoY) with ROE near 33% — a profitable institution at scale, not an early-stage fintech story.

The next lever is monetization: Brazil ARPU near $17 vs. roughly $40–$45 at traditional banks, with older cohorts already producing more revenue. Small-business coverage and Mexico/Colombia still leave room to grow.

U.S. and other international moves (including a banking charter path and multicurrency products) require spend and can pressure near-term earnings. LatAm remains the core; even a small foothold abroad can matter if the digital-banking model travels.

Broadcom — AI infrastructure and custom semis at huge scale. Oscar — membership growth plus efficiency into durable margins. Voyager — high-upside space/defense execution risk. Nu — monetize a massive customer base and expand carefully.

Useful questions: Can Broadcom’s AI growth persist at size? Can Oscar turn growth into durable margins? Can Voyager commercialize Starlab and contracts? Can Nu lift ARPU while funding new markets?

Price is easy to watch; the business decides whether that price is justified. Track revenue growth, margins, cash generation, customer growth, market share, and the size of the opportunity still ahead.

None is guaranteed to double — a projection is not a promise. For you, the goal is not to pick “the next winner.” It is to understand what has to go right for the investment thesis to work — and what evidence would tell you that it is no longer working.

Sponsored resource

Thanks for reading. This format is built to be fast to open, clear to understand, and useful enough to act on — without pretending past returns continue forever.

Disclaimer: This newsletter is for informational purposes only and is not financial advice. Consult a qualified advisor before investing.